Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Harmony Biosciences Holdings, Inc. (HRMY) Q3 2025 Earnings Call Transcript
Harmony Biosciences Holdings, Inc. ( HRMY ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Matthew Beck Jeffrey Dayno - President, CEO & Director Adam Zaeske - Executive VP & Chief Commercial Officer Kumar Budur - Executive VP and Chief Medical & Scientific Officer Sandip Kapadia - Executive VP, Chief Administrative Officer & CFO Conference Call Participants Ami Fadia - Needham & Company, LLC, Research Division David Amsellem - Piper Sandler & Co., Research Division Graig Suvannavejh - Mizuho Securities USA LLC, Research Division Jay Olson - Oppenheimer & Co. Inc., Research Division Pete Stavropoulos - Cantor Fitzgerald & Co., Research Division Danielle Brill Bongero - Truist Securities, Inc., Research Division Patrick Trucchio - H.C. Wainwright & Co, LLC, Research Division Ashwani Verma - UBS Investment Bank, Research Division David Hoang - Deutsche Bank AG, Research Division Presentation Operator Good morning.
Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings Miss Estimates
Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.87 per share, missing the Zacks Consensus Estimate of $0.92 per share. This compares to earnings of $0.79 per share a year ago.
Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: Should You Buy?
Harmony Biosciences (HRMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Harmony Biosciences: Reiterating Buy Ahead Of Data Catalyst For Cannabinoid Drug
Harmony Biosciences remains a Buy due to strong Wakix growth, profitability, and undervalued metrics despite recent setbacks. Upcoming catalysts—especially ZYN002 Phase 3 data in Fragile X—could drive significant upside, with >25% share price potential if successful, in my view. Pipeline diversification (pitolisant HD, GI, OX2R agonist, EPX-100) aims to offset Wakix patent expiry and expand long-term revenue streams.
Harmony Biosciences Holdings, Inc. (HRMY) Q2 2025 Earnings Call Transcript
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Adam Zaeske - Executive VP & Chief Commercial Officer Brennan Doyle - VP & Head of Investor Relations Jeffrey M. Dayno - President, CEO & Director Kumar Budur - Executive VP and Chief Medical & Scientific Officer Sandip S.
Harmony Biosciences Holdings, Inc. (HRMY) Misses Q2 Earnings and Revenue Estimates
Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.68 per share, missing the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.2 per share a year ago.
Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Harmony Biosciences (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Harmony Biosciences (HRMY) is Poised to Beat Earnings Estimates Again
Harmony Biosciences (HRMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
3 Reasons Growth Investors Will Love Harmony Biosciences (HRMY)
Harmony Biosciences (HRMY) could produce exceptional returns because of its solid growth attributes.
HRMY vs. ILMN: Which Stock Should Value Investors Buy Now?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Illumina (ILMN). But which of these two companies is the best option for those looking for undervalued stocks?
Does Harmony Biosciences (HRMY) Have the Potential to Rally 43.19% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 43.2% in Harmony Biosciences (HRMY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is Harmony Biosciences (HRMY) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
